370 results about "Drugs safety" patented technology

A method for assessing and analyzing one or more drugs, adverse effects and associated risks, and patient characteristics resulting from the use of at least drug of interest is disclosed. The method comprises the steps of selecting one or more cases for analysis, said cases describing the behavior between at least one drug of interest and a patient genotype; profiling statistically derived values from multiple cases related to the safety of the at least one drug, wherein at least one filter is employed for deriving said values; at least one data mining engine; and an output device for displaying the analytic results from the data mining engine. A system for performing the method is likewise disclosed.

The present invention relates to capsules for holding pharmaceutical preparations for powder inhalers with increased drug safety and capsules for pharmaceutical preparations for powder inhalers with improved adaptation to their use in powder inhalers. The capsules consist of water-insoluble hydrophobic synthetic materials which do not significantly affect the pharmaceutical quality of the contents themselves, but which improve the usability of the filled capsules with regard to their function, their longevity and/or the geographic location of their use, and are advantageous at various stages from manufacture up to utilisation.

A pharmaceutical composition with improved safety includes a selected amount of a vomit-inducing agent, wherein the selected amount is less than an amount needed to induce vomit in a user; and a therapeutic agent. The therapeutic agent may be selected from a sleeping pill, an anxiolytic, a hypnotic, a contraceptive agent. The therapeutic agent may also be selected from diazepam, flunitrazepam, alprazolam, triazolam, fludiazepam, midazolam, estazolam, zopiclone, and a combination thereof. The vomit-inducing agent may be selected from emetine, cephaeline, and a combination thereof.

The invention belonging to the technical field of medical data processing discloses an intelligent-algorithm-based drug safety confidence index system and a construction method. The construction method comprises: research data are collected; the research data are analyzed and a comprehensive evaluation index is obtained by a corresponding delphi method; and a drug safety evaluation index system is constructed and a PSO-BP-neural-network drug safety evaluation model is improved. The system is composed of a target layer, a project layer, a factor layer, and an index layer. According to the invention, a corresponding evaluation mode needs to be constructed in a future drug safety index analysis and the algorithm, data, and various factor weight ratios of drug safety evaluation index are analyzed in the evaluation result, so that the selected data source becomes accurate, the used algorithm meets the practical situation, and the constructed drug safety evaluation index is based on scientific, people-oriented, truth-seeking, rigorous, innovative principles.

The invention provides means to determine the predisposition of individuals to adverse drug reactions (ADRs). The methods are based on genotyping or parallelized enzyme and protein profiling or both. Parallelized enzyme activity profiling can be used for drug screening and development. As examples of the invention we show the prediction of adverse drug reactions of pulmonary hypertension patients by identifying genes and alleles linked to known ADRs and liver enzyme reaction profiling with ADR correlation.

A method for restricted distribution of a drug to a patient while minimizing the occurrence of adverse side effects. The method restricts access to the drug by preventing distribution to certain patients for whom the drug may be contraindicated. The method permits a prescription to be filled by a pharmacy only after the pharmacy has received an approval for release of the prescription. Generation of the prescription approval depends on registration of a prescriber, pharmacy and patient in a central database, and the determination that the risk is acceptable that the patient will experience an adverse side effect. The database contains a patient profile that may include additional patient-specific health-related information that is probative of the risk that an adverse side effect is likely to occur if the patient is exposed to the drug. Based in part on the information in the patient profile, the registered prescriber makes a determination as to the patient's risk of adverse side effects. If the registered prescriber determines that the risk is acceptable, a prescription request is generated. At the time that the prescription is to be dispensed to the patient, the pharmacy also makes a determination as to the patient's risk of adverse side effects. If the pharmacy determines that the risk is acceptable, the drug is dispensed to the patient. Additional steps may be taken to ensure compliance with the drug delivery method, such as education, oversight by a drug safety analyst, and/or regular contact with a representative.

The invention provides a tacrolimus sustained-release preparation and a preparation method thereof. The invention adopts a solid dispersion technology, or cyclodextrin inclusion technology or a solubilizing method for micronizing drugs and then adding one or more types of surfactants and the like, and obviously improves solubility thereof so as to improve the bioavailability thereof, then adds oneor more types of skeleton materials and other auxiliary materials so as to prepare a skeleton type sustained-release preparation, or adopts a sustained-release material to carry out coating so as toprepare a diaphragm-controlled type or osmotic pump type sustained-release preparation. The tacrolimus sustained-release preparation has better solubility and dissolution rate, high bioavailability and sustained-controlled-release effect, thus maintaining stable blood and drug concentration, reducing the occurrence rate of adverse reaction, and improving clinical drug safety; in addition, the invention has easy obtaining for materials, simple and feasible preparation technique, high yield and low cost, can realize large-scale industrialized production and has obviously economical benefit.

The present invention is a system and method for utilizing human genetic and genomic information to guide prescription dispensing and improved drug safety in a pharmacy setting. The system and method of the present invention utilizes a dedicated information management system and software to utilize patient-specific genetic information to screen for increased risk of adverse drug reactions and therapeutic responses at the time of drug dispensing.

The invention discloses a distributed intelligent drug safety management system. The distributed intelligent drug safety management system comprises an upper computer terminal and an intelligent cabinet terminal. A laboratory information management system is installed in the upper computer terminal, and the upper computer terminal is connected with and has communication with a fingerprint reader and a POS miniature printer. The intelligent cabinet terminal comprises a cabinet and an intelligent control terminal, and the intelligent control terminal is connected with a liquid crystal display and used for displaying drug list information, drug using information and cabinet using conditions. A plurality of small cabinet bodies are installed on the cabinet and distributed in an array mode. The upper computer terminal is connected with the intelligent control terminal through the TCP/IP, after mutual authentication succeeds, communication is achieved, and the intelligent control terminal is used for controlling the cabinet to be opened and closed. The system has the advantages of being safe in management, intelligent in control, user-friendly in operation, easy to extend and maintain and capable of effectively achieving safe and effective storage and informatization management of agents and drugs in the fields of materials, chemistry and medicines.

The invention provides an aptamer electrode for detecting terramycin. The electrode is characterized in that a glassy carbon electrode is sequentially modified with a graphene-gold nanometer compound and a BSA-OTC compound from bottom to top. A signal layer is methylene blue modified aptamer having a G tetrad structure and folded under an RCA chain amplification reaction, and the content of a target product is reflected through the amount of methylene blue. The invention also provides a manufacturing method of the aptamer electrode. The aptamer electrode has the advantages of simple manufacturing method, stable performances, and good repeatability, and is suitable for terramycin detection in the medicine safety and the industrialized practical application of biosensors.

The invention discloses a detection method for the CYP2C9 gene ninth exon single nucleotide polymorphism, belonging to the technical field of the genetic engineering. The method comprises the following steps: step one, by taking the CYP2C9 gene ninth exon in a GenBank database and the exon and intron joint part sequence as a template, a pair of allele-specific nucleic acid primers are designed; the primer pair is used for amplifying the DNA sequence of the CYP2C9 gene ninth exon; and then corresponding separated nucleic acids are obtained by conducting separation and purification on the amplified product; and step two, detection is carried out on the 1739-1740 nucleotides of the CYP2C9 gene ninth exon of the separated nucleic acids so as to fix whether single nucleotide polymorphism exists or not. The invention can be used for studying the relationship between the CYP2C9 gene polymorphism in the population of China and the clinical drug safety, and provides guiding basis for the research and development of new drugs.

The invention relates to a pharmaceutical composition containing mosapride citrate. The pharmaceutical composition contains lactose and other pharmaceutically acceptable accessory materials. Through strict control of a mass ratio of lactose to water in the pharmaceutical composition, mosapride citrate long-term storage stability is greatly improved and related substance generation and increasing risk is reduced. The pharmaceutical composition provides guarantee for clinical drug safety and effectiveness.

The invention discloses a food and drug supervision system and method based on gridding management. The supervision system comprises a cloud computing platform, a database platform, a gridding management platform and a mobile terminal user application platform, the gridding management platform is used for dividing the supervision range into grids, and food and drug production and circulation information of all supervision enterprises in the grids is marked on a geographic map information module (GIS); The supervision method comprises the steps of administrative supervision, technical supervision and inspection case handling, and inspection case handling comprises the steps of grid division, information collection, task providing, task dispatching, task processing, processing feedback, casechecking and checking and comprehensive evaluation. According to the invention, a food safety supervision system based on a GIS professional map for prevention is established, food and drug safety production and circulation process supervision are realized, and food and drug quality safety is guaranteed.

The present invention provides methods for performing pharmacological profiling of a chemical compound, in particular to improve drug safety and efficacy at an early stage in the drug development process. The chemical compound may be a test compound, drug lead, known drug or toxicant. The compound is profiled against a panel of assays. Preferred embodiments of the invention include high-content assays for protein-protein interactions. The compositions and methods of the invention can be used to identify pathways underlying drug efficacy, safety, and toxicity; and to effect attrition of novel compounds with undesirable or toxic properties. The compositions and methods of the invention can also be used to identify new uses of therapeutic agents, to screen libraries of chemical compounds, to perform lead optimization, and to perform studies of structure-activity relationships in the context of intact cells. The compositions and methods of the invention can be applied to any test compound, drug, drug target, pathway, and therapeutic indication.

The invention relates a new active clindamycin phosphate compound and a medicinal composition of the compound. When the clindamycin phosphate compound is determined by using powder X-ray diffraction, characteristic diffraction peaks appear at the angels of 4.85 degrees, 5.73 degrees, 6.64 degrees, 9.12 degrees, 11.98 degrees, 13.51 degrees, 17.37 degrees, 19.61 degrees, 21.76 degrees, 22.23 degrees, 23.46 degrees, 26.82 degrees, 28.16 degrees, 33.68 degrees and 34.29 degrees in a X-ray diffraction pattern represented in 2theta +/-0.2 degree diffraction angles. The stability of the clindamycinphosphate compound provided by the invention is improved remarkably; the influences on the appearance, content and other aspects of the clindamycin phosphate compound caused by long-term storage can be ignored, thereby ensuring the drug safety for patients. In addition, the new clindamycin phosphate compound is suitable to be popularized and applied to various clindamycin phosphate preparations.

The invention discloses a primer set for quickly identifying truth of beauveria bassiana in Chinese herbal medicine stiff silkworm and a molecular identifying method. The sequence of the primer set is respectively shown as SEQ ID NO.1-2. According to the invention, on the basis of the completion of high-throughput sequencing of complete genome of Guangdong beauveria bassiana mitochondria and bioinformatic comparative analysis of mitochondria complete genome of multiple cordyceps species, the difference of the beauveria bassiana mitochondria gene sequences at the aspect of geographical species is compared and obvious variation of ribosomal protein gene of beauveria bassiana is founded; a pair of primers for specifically detecting beauveria bassiana are screened on the basis of the design; the molecular identifying method for quickly and efficiently identifying truth of beauveria bassiana in Chinese herbal medicine stiff silkworm is established; the method is simple, convenient and quick, has high specificity, high sensitivity and wide application scope and can realize the identification for the truth of the beauveria bassiana from different producing places; a technical support is supplied for quality standardization and normalization and clinic drug safety of the Chinese herbal medicine stiff silkworm.

The invention relates to the field of medicinal chemical synthesis and in particular relates to a synthetic method of perampanel, an intermediate of the perampanel and a synthetic method of the intermediate. The provided synthetic method of the perampanel comprises the following steps: carrying out a cyclization reaction on a compound shown in a formula V and a compound shown in a formula VI, so that a compound shown in a formula VII is obtained, wherein the formulas V, VI and VII are described in the specification, and R1 is alkyl amino, amino or alkoxy. The invention also aims at providing a synthetic method of an intermediate of the perampanel. In a synthetic process, phenyl, cyano phenyl and 2-pyridyl are sequentially introduced, compared with the prior art, a sequence of introducing substituent groups is changed, so that the problems that reaction yield is low and byproducts are many and can not be removed as 2-pyridyl is firstly introduced and then cyano phenyl is introduced can be solved; a route is changed, and a Pd containing catalyst is not used in reaction of the last step, so that Pd residue is reduced, drug safety is improved, and reaction yield and product purity are greatly improved, so that the synthetic method of the perampanel is applicable to industrial production.

The present invention relates to the use of genetic variants of associated marker genes to predict an individual's susceptibility to muscular injury and muscular side effects in response to statin therapy. The present invention further relates to analytical assays and computational methods using the novel marker gene set. The present invention has utility for personalized medical treatment, drug safety, statin compliance, and prophylaxis of muscle side effect.

The invention discloses a ligustrum lucidum and the new use for Chinese medicine of a ligustrum lucidum extractive for preparing medicines for prevention or treatment of osteoporosis, and also discloses a granule for prevention or treatment of osteoporosis, wherein, the granule comprises 25 to 35 percents of the ligustrum lucidum extractive and 65 to 75 percents of an excipient which chooses sucrose and dextrine, or is made into capsules. The capsules contain the ligustrum lucidum extractive. The ligustrum lucidum single-taste and the relative pharmaceutical preparation of the invention has the advantages of accurate curative effect, low side effects, more drug safety, simple preparation craft and lower cost in the application of prevention or treatment of osteoporosis.

The invention relates to an oral anti-tumor drug capecitabine granule and a preparation method thereof. The capecitabine granule exists in the form of a cyclodextrin inclusion compound and is prepared from capecitabine serving as a raw material drug and auxiliary materials comprising cyclodextrin, a diluting agent, a disintegrating agent, an adhesive and a flavoring agent by wet granulation. The capecitabine granule disclosed by the invention not only covers the bitterness of a capecitabine drug and enhances the drug compliance of a cancerous person, but also enhances the stability of the capecitabine in gastrointestinal tracts and accelerates the digestion velocity, thereby preventing the peak valley phenomenon of the blood concentration of a drug, outstandingly reducing the adverse reactions of the drug, such as irritation and toxic side effect, on the gastrointestinal tracts due to the stable release of capecitabine in the gastrointestinal tracts, enhancing the drug safety and better taking the anti-tumor effect.

The invention provides a clean and highly efficient preparation method of soybean isoflavone glycoside. The steps include dissolving degreasing soybean powder or soybean meal in water or buffer solution to prepare material solution; adding Beta-glucosidase in the material solution for the hydrolysis; adding ethanol in precipitates after the enzymatic hydrolysis for the extracting and the filtering to remove residues. A soybean isoflavone glycoside product is obtained after the vacuum concentration of the filtering solution. The invention changes an original two-step method of extracting soybean isoflavone and biologically transforming the soybean isoflavone into aglycone, uses the Beta-glucosidase with heat resistance in an extract process and directly uses the soybean meal or the degreasing soybean powder to prepare the soybean isoflavone glycoside. The soybean isoflavone in raw materials are being thermally extracted while being transformed. The inhibition effect of high concentrated initial substrates on the enzyme catalysis is avoided. The response speed is greatly increased. The enzyme hydrolysis efficiency is improved. Compared with the present enzymatic extraction, the invention has the advantages of short production cycle, simple operation, high yield, low cost and pollution-free property. And the obtained products are applied to food or drug safety.